In anticipation of PhIII trial results, Amicus pares down old debt with $400 million loan

Amicus received a healthy heaping of good news last month when analysts threw cold water on Sanofi’s late-onset Pompe disease ERT, after a Phase III study essentially cleared the way for Amicus’ competing candidate to be the standard-bearer. Now, Amicus is preparing for a new “path to profitability” with an expected windfall.